File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Inhibition of breast cancer cell proliferation and migration by monoclonal antibody m590 specific for insulin-like growth factor receptor type I

TitleInhibition of breast cancer cell proliferation and migration by monoclonal antibody m590 specific for insulin-like growth factor receptor type I
抗胰島素樣生長因子I型受體單克隆抗體M590抑制乳腺癌細胞增生和遷移
Authors
KeywordsBreast carcinoma (乳腺癌)
Insulin-like growth factor receptor type I (胰島素樣生長因子I型受體)
Proliferation (增生)
Migration (遷移)
Issue Date2012
PublisherHubei Medical Association (湖北省醫學會).
Citation
Chinese Journal of Experimental Surgery, 2012, v. 29 n. 5, p. 824-826 How to Cite?
中華實驗外科雜誌, 2012, v. 29 n. 5, p. 824-826 How to Cite?
AbstractObjective To investigate the mechanism(s) that a human-mouse chimeric monoclonal anti-insulin-like growth factor receptor type Ⅰ (IGF-IR) antibody,m590,inhibits breast cancer cells proliferation and migration.Methods Binding of m590 to IGF-IR in 30 breast cancer samples was detected by using immunohistochemistry.Western blotting,immunocytofluorescence and other tests were used for analyzing the effects of m590 on breast cancer cells ( MCF-7 ) proliferation,survival,adhesion and migration as well as signaling pathways.Results m590 specifically bound to IGF-IR was overexpressed in invasive ductal carcinoma of the breast (87% of cases).Treatment of MCF-7 cells with m590 significantly suppressed IGF-I-induced phosphorylation of ERK and Akt,which led to reduced cell proliferation by 58%and increased apoptosis.m590 also inhibited IGF-Ⅰ-induced polymerization of F-actin and relocation of vinculin in cell edge,resulting in dramatically decreased cell migration by 56% and cell adhesion by 55%.Furthermore,herceptin in combination with m590 synergistically inhibited IGF-IR-induced phosphorylation of ERK and AKT,and decreased MCF-7 cells proliferation by 76% as compared with IGF-I treatment alone.Conclusion m590 is an effective anti-IGF-IR antibody and may have the potential in clinical use for diagnosis and treatment of breast cancer.
目的探討抗胰島素樣生長因子Ⅰ型受體(IGF-IR)抗體,m590,抑制乳腺癌細胞增生、遷移及其機制.方法免疫組織化學染色30例乳腺浸潤性導管癌標本;免疫印跡法、免疫熒光細胞染色及其他試驗檢測m590 對MCF-7細胞的作用及其機制.結果87%的乳腺浸潤性導管癌高表達IGF-IR;m590抑制胰島素樣生長因子Ⅰ(IGF-I)誘導的細胞外調節蛋白激酶(ERK)和蛋白激酶B(Akt)磷酸化以及細胞骨架蛋白(F-actin)和細胞骨架黏合班蛋白(Vinculin)在細胞內的分佈,使細胞增生、遷移和黏附分別降低至5​​8 %、56%和55%,並促進細胞凋亡;M590 與赫賽汀聯用抑制IGF-I誘導的ERK和Akt 磷酸化,使細胞增生降低76%.結論m590 是一個有效抑制乳腺癌細胞增生、遷移和黏附的抗IGF-IR抗體.
Persistent Identifierhttp://hdl.handle.net/10722/159708
ISSN

 

DC FieldValueLanguage
dc.contributor.authorFu, XYen_US
dc.contributor.authorChen, Cen_US
dc.contributor.authorPan, HXen_US
dc.contributor.authorHuang, Ten_US
dc.contributor.authorZhang, MYen_US
dc.contributor.authorZheng, Hen_US
dc.date.accessioned2012-08-16T05:54:45Z-
dc.date.available2012-08-16T05:54:45Z-
dc.date.issued2012en_US
dc.identifier.citationChinese Journal of Experimental Surgery, 2012, v. 29 n. 5, p. 824-826en_US
dc.identifier.citation中華實驗外科雜誌, 2012, v. 29 n. 5, p. 824-826-
dc.identifier.issn1001-9030-
dc.identifier.urihttp://hdl.handle.net/10722/159708-
dc.description.abstractObjective To investigate the mechanism(s) that a human-mouse chimeric monoclonal anti-insulin-like growth factor receptor type Ⅰ (IGF-IR) antibody,m590,inhibits breast cancer cells proliferation and migration.Methods Binding of m590 to IGF-IR in 30 breast cancer samples was detected by using immunohistochemistry.Western blotting,immunocytofluorescence and other tests were used for analyzing the effects of m590 on breast cancer cells ( MCF-7 ) proliferation,survival,adhesion and migration as well as signaling pathways.Results m590 specifically bound to IGF-IR was overexpressed in invasive ductal carcinoma of the breast (87% of cases).Treatment of MCF-7 cells with m590 significantly suppressed IGF-I-induced phosphorylation of ERK and Akt,which led to reduced cell proliferation by 58%and increased apoptosis.m590 also inhibited IGF-Ⅰ-induced polymerization of F-actin and relocation of vinculin in cell edge,resulting in dramatically decreased cell migration by 56% and cell adhesion by 55%.Furthermore,herceptin in combination with m590 synergistically inhibited IGF-IR-induced phosphorylation of ERK and AKT,and decreased MCF-7 cells proliferation by 76% as compared with IGF-I treatment alone.Conclusion m590 is an effective anti-IGF-IR antibody and may have the potential in clinical use for diagnosis and treatment of breast cancer.-
dc.description.abstract目的探討抗胰島素樣生長因子Ⅰ型受體(IGF-IR)抗體,m590,抑制乳腺癌細胞增生、遷移及其機制.方法免疫組織化學染色30例乳腺浸潤性導管癌標本;免疫印跡法、免疫熒光細胞染色及其他試驗檢測m590 對MCF-7細胞的作用及其機制.結果87%的乳腺浸潤性導管癌高表達IGF-IR;m590抑制胰島素樣生長因子Ⅰ(IGF-I)誘導的細胞外調節蛋白激酶(ERK)和蛋白激酶B(Akt)磷酸化以及細胞骨架蛋白(F-actin)和細胞骨架黏合班蛋白(Vinculin)在細胞內的分佈,使細胞增生、遷移和黏附分別降低至5​​8 %、56%和55%,並促進細胞凋亡;M590 與赫賽汀聯用抑制IGF-I誘導的ERK和Akt 磷酸化,使細胞增生降低76%.結論m590 是一個有效抑制乳腺癌細胞增生、遷移和黏附的抗IGF-IR抗體.-
dc.languagechien_US
dc.publisherHubei Medical Association (湖北省醫學會).-
dc.relation.ispartofChinese Journal of Experimental Surgeryen_US
dc.relation.ispartof中華實驗外科雜誌-
dc.subjectBreast carcinoma (乳腺癌)-
dc.subjectInsulin-like growth factor receptor type I (胰島素樣生長因子I型受體)-
dc.subjectProliferation (增生)-
dc.subjectMigration (遷移)-
dc.titleInhibition of breast cancer cell proliferation and migration by monoclonal antibody m590 specific for insulin-like growth factor receptor type Ien_US
dc.title抗胰島素樣生長因子I型受體單克隆抗體M590抑制乳腺癌細胞增生和遷移-
dc.typeArticleen_US
dc.identifier.emailZhang, MY: zhangmy@hku.hken_US
dc.identifier.authorityZhang, M=rp01409en_US
dc.identifier.doi10.3760/cma.j.issn.1001-9030.2012.05.016-
dc.identifier.hkuros202161en_US
dc.identifier.volume29en_US
dc.identifier.issue5-
dc.identifier.spage824-
dc.identifier.epage826-
dc.publisher.placeChina (中國)-
dc.customcontrol.immutablecsl 150210-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats